Clinical Focus Targeting Alzheimer’s disease with T3D-959 as a potential first-in-class therapy presents a clear market entry point for clinicians, researchers, and payer discussions; leverage ongoing biomarker studies and pre-clinical Huntington’s work to broaden collaborations with neurology departments and research consortia.

Funding Signals Previous grant and grant-backed funding from NIH/NIA and Alzheimer's Association indicate receptivity to collaborative funding models; use this to pursue co-development, joint research, and grant-aligned partnerships with academic centers and biotech co-funding opportunities.

Clinical Stage As a clinical-stage company with a focused lead candidate, there is opportunity to partner for Phase 2/3 biomarker-driven trials, contract manufacturing, and accelerated access programs with larger pharma firms seeking innovative CNS therapies.

Strategic Partnerships Engage with research institutions, contract research organizations, and specialty pharmacies that support CNS drug development and biomarker analytics to accelerate study milestones, data generation, and potential co-commercialization avenues.

Financing Momentum Historical fundraising activity at multiple stages signals potential for strategic investors and industry partners; approach with sell-side advisory and business development pitches that align T3D-959 development milestones with co-investment or milestone-based licensing opportunities.